{"entity":{"id":"genemedicine","kind":"company","name":"GeneMedicine","aka":["진메디신"],"tldr":"GeneMedicine is a South Korean company developing viruses that attack cancer cells. Its lead product, GM103, is injected into tumours and is in an early trial alone and with the immunotherapy pembrolizumab.","summary":"GeneMedicine Co., Ltd. is based at the Hanyang University Fusion Technology Center in Seongdong-gu, Seoul, and says it develops next-generation anticancer viruses. GM103 is given by intratumoural injection in the phase 1/2 trial NCT06265025, alone and with pembrolizumab, in locally advanced or metastatic solid tumours including head and neck, colorectal, melanoma, renal cell, cervical and breast cancers. Its first registered cancer trial, NCT06265025, was posted on ClinicalTrials.gov in February 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.gene-medicine.com/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06265025"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website (footer reads 2019).","The viral platform behind GM103 is not described in text on the pages read.","No financing amounts stated; the site lists a new share issuance notice dated 23 April 2025 without terms.","Company website read on 29 October 2026."],"hq":"Seoul","country":"KR","companyType":"biotech","website":"https://www.gene-medicine.com/","investors":[],"funding":[]},"route":"/companies/genemedicine/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"trial":[{"id":"nct06265025","kind":"trial","name":"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors","route":"/trials/nct06265025/"}]}}